Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure

The effect of pathophysiology on pharmacokinetics in the critically ill patient — Concepts appraised by the example of antimicrobial agents

(2014) Stijn I. Blot et al.   ADVANCED DRUG DELIVERY REVIEWS

Pharmacokinetics of caspofungin in ICU patients

(2014) E. W. Muilwijk et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis

(2013) Gudrun Würthwein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-Fourths

(2013) Ronald G. Hall et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Body Mass Index Is Associated With Hospital Mortality in Critically Ill Patients

(2013) Peter Pickkers et al.   CRITICAL CARE MEDICINE

A Pharmacokinetic Standard for Babies and Adults

(2013) Nick Holford et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials

(2012) D. R. Andes et al.   CLINICAL INFECTIOUS DISEASES

Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients

(2011) Gudrun Würthwein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese People

(2011) Ronald G. Hall et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

(2011) O. A. Cornely et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species

(2010) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

(2010) Ron J. Keizer et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Echinocandin pharmacodynamics: review and clinical implications

(2010) M. W. Pound et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis

(2009) Robert F. Betts et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans

(2009) Brian J. Anderson et al.   Drug Metabolism and Pharmacokinetics

International Study of the Prevalence and Outcomes of Infection in Intensive Care Units

(2009) Jean-Louis Vincent   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

(2008) D. R. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY